| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Hepcidin, Liver-expressed antimicrobial peptide 1, LEAP-1, Putative liver tumor regressor, PLTR, Hepcidin-25, Hepc25, Hepcidin-20, Hepc20, HAMP, HEPC, LEAP1 |
| Entrez GeneID | 57817 |
| WB Predicted band size | 9.4kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This HAMP antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 17-46 amino acids from the Central region of human HAMP. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于HAMP(hepcidin)抗体的3篇代表性文献及其摘要概括：
1. **文献名称**：*Development of a Monoclonal Antibody-Based ELISA for Detection of Human Hepcidin in Serum*
**作者**：Kulaksiz H, et al. (2018)
**摘要**：该研究开发了一种高特异性单克隆抗体，用于检测人血清中的hepcidin水平，为铁代谢紊乱疾病的诊断提供了可靠工具，验证了抗体在临床样本中的敏感性和准确性。
2. **文献名称**：*Antibody-Mediated Inhibition of Hepcidin Corrects Iron Metabolism in a Mouse Model of Anemia of Chronic Disease*
**作者**：Nicolas G, et al. (2020)
**摘要**：通过靶向抑制hepcidin的单克隆抗体，成功恢复小鼠模型中铁代谢平衡，改善慢性病贫血症状，证明抗体疗法在调节铁稳态中的治疗潜力。
3. **文献名称**：*Therapeutic Targeting of Hepcidin in Iron Disorders: Preclinical Studies with a Humanized Anti-Hepcidin Antibody*
**作者**：Sasu BJ, et al. (2017)
**摘要**：研究报道了一种人源化抗hepcidin抗体在动物模型中的效果，显示其能有效阻断hepcidin功能，增加血清铁水平，为治疗缺铁性贫血和慢性肾病贫血提供依据。
(注：以上文献信息为模拟示例，实际引用需以真实出版物为准。)
Hepatocyte-produced hepcidin antimicrobial peptide (HAMP), commonly known as hepcidin, is a key regulator of systemic iron homeostasis. This 25-amino-acid peptide hormone, encoded by the HAMP gene, controls dietary iron absorption in the duodenum and iron recycling by macrophages. By binding to the iron exporter ferroportin, hepcidin induces its internalization and degradation, thereby reducing serum iron levels. Dysregulation of HAMP is implicated in various iron-related disorders: insufficient hepcidin causes iron overload (e.g., hereditary hemochromatosis), while excessive production contributes to iron-restricted anemias like anemia of chronic disease.
HAMP antibodies have emerged as critical tools for both research and therapeutic development. In diagnostics, they enable quantification of circulating hepcidin levels to assess iron status. Therapeutically, monoclonal antibodies targeting hepcidin or its regulatory pathways are being explored to treat iron disorders. For instance, anti-hepcidin antibodies may block its activity to improve iron availability in anemia, while agonists might enhance hepcidin function to mitigate iron overload. Recent studies also investigate HAMP antibodies in cancer-related anemia and inflammatory conditions where iron metabolism is disrupted. Despite challenges in maintaining hormone-level specificity, HAMP-targeting antibodies represent a promising approach for modulating iron physiology.
×
